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ABSTRACT.
Purpose: Antivascular endothelial growth factor agents are increasingly used in diabetic macular oedema (DME); however, there are
few studies exploring their use in DME in real-world settings.
Methods: POLARIS was a noninterventional, multicentre study to monitor 12-month outcomes in patients starting ranibizumab
treatment in routine practices. The primary outcome was mean change in visual acuity (VA) from baseline to month 12 (last observation
carried forward approach). Other outcomes included mean change in central retinal thickness (CRT) and resource utilization. Visual
acuity (VA) outcomes were also stratified by country, baseline visual acuity score (VAS), sex, age and injection frequency.
Results: Outcomes were analysed from all treated patients (n = 804) and from first-year completers (patients who had a visual acuity
assessment at 12 months; n = 568). The mean (SD) baseline VAS was 59.4 (15.9) letters, and the mean change in visual acuity was 4.4 letters
(95% confidence interval: 3.3–5.4) at month 12 (study eye; first-year completers). The mean number of injections (study eye) was 4.9, and the
mean number of all visits (any eye)was 10 (58%were injection visits) over 12 months (first-year completers). Themean (SD) baselineCRTwas
410.6 (128.8) lm, and the mean change in CRT was115.2 lm at month 12 (study eye; first-year completers). Visual acuity (VA) outcomes
were generally comparable across most countries and subgroups and were greatest in patients with the lowest baseline VAS (≤60 letters).
Conclusion: POLARIS showed that real-world outcomes in DME patients starting treatment with ranibizumab were lower than those
observed in clinical studies, in spite of extensive monitoring.
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Introduction
It is estimated that 285 million adults
worldwide currently have diabetes mel-
litus, with 31 million having vision-
threatening diabetic retinopathy or
diabetic macular oedema (DME) (Lee
et al. 2015). Diabetic macular oedema
can occur at any stage of retinopathy
and is typically characterized by retinal
thickening and leakage of extracellular
ﬂuid, which are linked with hypoxia
and upregulation of vascular endothe-
lial growth factor (VEGF) (Fong et al.
2003). Current treatment options
include laser photocoagulation and dex-
amethasone implants. Laser is eﬀective
in stabilizing disease, but its ability to
reverse vision loss is low. Laser is also
associated with thermal complications,
which can still manifest many years
after treatment (Early Treatment Dia-
betic Retinopathy Study Research
Group 1985; Cheung et al. 2010). Since
their introduction, anti-VEGF agents
have been used increasingly in the
treatment of DME (Jiang et al. 2015;
Dugel et al. 2016). These agents not
only target VEGF, notably VEGF-A,
but are clinically eﬀective and well
tolerated in randomized studies in
patients with DME (Mitchell et al.
2011; Nguyen et al. 2012; Papadopou-
los et al. 2012; Simo et al. 2014; Wells
et al. 2015, 2016; Prunte et al. 2016).
A direct comparison of three anti-
VEGF agents [ranibizumab 0.3 mg,
intravitreal aﬂibercept (IVT-AFL)
2 mg and bevacizumab 1.25 mg] in the
Protocol T study showed that all agents
were eﬀective in improvingVAat 1 year
(the primary outcome) and over 2 years
in patients with DME, but IVT-AFL
was signiﬁcantly more eﬀective at
improving 1-year outcomes in patients
with worse baseline VA (<69 letters)
comparedwith ranibizumab (p = 0.003)
and bevacizumab (p < 0.001) (Wells
et al. 2015, 2016). However, the Dia-
betic Retinopathy Clinical Research
Network added that caution must be
exercised when extrapolating these
results into routine clinical practices
(Heier et al. 2016). This is particularly
important for considering any clinical
diﬀerences between the US Food and
Drug Administration–approved dose of
ranibizumab (0.3 mg), which was used
inProtocolT, and theEuropeanUnion–
approved dose (0.5 mg). In addition,
these studies did not consider the impact
of the recent European label change for
ranibizumab; the recommended
approach was switched from as-needed
with monthly monitoring to a more
ﬂexible regimen. Observational studies
in other indications, such as neovascular
age-related macular degeneration
(nAMD), have shown that ranibizumab
dosing is low and VA outcomes are not
maintained over time (Writing Commit-
tee for the UK Age-Related Macular
Degeneration EMRUsersGroup. 2014;
Holz et al. 2015, 2016a,b). Such studies
were also performed when ranibizumab
had a less ﬂexible regimen per label. To
date, there are a few small studies
exploring these issues in patients with
DME (Brynskov et al. 2013; Hrarat
et al. 2016; Patrao et al. 2016).
POLARIS was an international,
large-scale, noninterventional, multi-
centre study to monitor 12-month out-
comes in patients with DME who
started treatment with ranibizumab
(this was the only anti-VEGF agent
approved at the start of this study).
This study aimed at reﬂecting a real-
world setting, and any subsequent
treatment decisions were made by the
treating physician in accordance with
their normal routine practice. Patients
were enrolled from clinical practices
across eight European countries.
Patients and Methods
Study design
POLARIS (NCT01771081) was a non-
interventional, real-world study to
monitor 12-month outcomes and
resource use in patients with DME
who started treatment with ranibizu-
mab. The study was conducted from 27
September 2012 (ﬁrst patient visit) to
30 January 2015 (last patient visit) in
75 centres across eight European coun-
tries: France, Germany, Greece, Portu-
gal, Russia, Slovakia, Spain and the
UK. The protocol and its amendments
were approved by the independent
ethics committees and institutional
review boards for all participating cen-
tres as required by country laws and
regulations.
Participants
Patients diagnosed with type 1 or 2
diabetes mellitus and DME with cen-
tral involvement, which was deﬁned as
the centre subﬁeld area on optical
coherence tomography (OCT), were
enrolled. Patients were enrolled after
the diagnosis and decision to treat
DME with ranibizumab had been
made by the physician, and patients
had to receive the ﬁrst treatment on or
after 01 October 2012. Patients were
excluded if they had received any anti-
VEGF prior to study enrolment or if
they had participated in any investiga-
tional study. To reduce selection bias,
each consecutive patient examined dur-
ing the observation period had to be
screened and documented in an anony-
mous patient log ﬁle (independent of
prescribed treatment), including infor-
mation on the treatment given. All
patients provided written informed
consent to participate.
Treatment and data collection
Patients started treatment with ranibi-
zumab (this was the only anti-VEGF
agent approved at the start of this
study). Any retreatment decisions (in-
cluding interval and dose) were made by
the treating physician in accordance
with their normal routine practice. As
this study aimed at reﬂecting a real-
world setting, patients could also receive
ocular surgeries, laser or switch to other
available anti-VEGF agents such as
pegaptanib sodium or bevacizumab
based on the physician’s decisions and
usual practice (IVT-AFL was not
approved or available for this indication
at the time of study start). These patients
were included in the analyses. This
decision was preplanned to monitor
actual treatment use and associated
outcomes in a real-world setting.
Patients were followed up for
12 months during routine (treatment
and monitoring) visits. Information on
study eye(s), drug, dose and date
administered, together with the reasons
for discontinuation or retreatment, was
recorded. All data were collected by
study investigators who were blinded
to patient details, and patients were
identiﬁed by a central identiﬁcation
code only.
Patients could be enrolled prospec-
tively (i.e. ﬁrst treatment on/after 01
October 2012 with prospective follow-
up) or retrospectively (i.e. data col-
lected retrospectively from the date of
ﬁrst treatment with prospective follow-
up) from enrolment; this allowed suﬃ-
cient numbers to be consecutively
included without prolonging recruit-
ment. Data were collected from medical
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records, patient interviews or during
initial and follow-up visits, and included
socio-demographic characteristics, med-
ical history, previous and current DME
therapy and routine tests. All data were
provided by the treating ophthalmolo-
gist/physician and recorded in electronic
case report forms, which were audited
for accuracy using source data veriﬁca-
tion overseen by the sponsor (Bayer
AG, Berlin, Germany).
Assessments
Data were recorded using both eyes
(study eye/fellow eye), but only out-
comes in the study eye were included in
analyses. The study eye was deﬁned as
the eyewith theworse visual acuity (VA)
at the start of therapy. However, if both
eyes had the same VA at therapy start,
then the right eye was deﬁned as the
study eye. In the case of bilateral
disease, the second eye treated (treated
fellow eye) was analysed separately. The
primary outcome was the mean change
in VA (letters) from baseline up to
month 12. As the study was noninter-
ventional, VA was measured according
to physician’s own practice [e.g. Early
Treatment Diabetic Retinopathy Study
(ETDRS) letters, Snellen fractions or
logarithm of the minimum angle of
resolution (logMAR)] and was con-
verted to a standardized visual acuity
score (VAS) (letters) using published
conversion charts (Ferris et al. 1982;
Holladay 1997; Gregori et al. 2010).
Additional data were collected on the
socio-demographic and clinical proﬁle
of the patient; resource utilization (vis-
its, injections and diagnostics) including
the proportion of patients requiring
laser therapy and mean change in cen-
tral retinal thickness (CRT) on OCT
were recorded. The use of OCT (any
type) as an assessment depended on the
clinic’s access to it, and need for it, and
would therefore vary during the study.
All spectral domain measurements were
subtracted with 43.1 lm to ﬁt the
measurements of the time domain
machines.
Statistical analyses
A sample size of 330 patients was
required to estimate the change from
baseline in VA (letters) within a 95%
conﬁdence interval (CI) of 1.5 let-
ters. This assumed a 95% probability
of obtaining a CI with a width of ≤3
letters using a standard deviation (SD)
of 13 for the change in VA. To ensure
that POLARIS was reasonably well
matched against the additional criteria
used in the VIVID/VISTA-DME and
RESTORE studies (Mitchell et al. 2011;
Korobelnik et al. 2014), it was assumed
that a higher patient number would be
needed mainly to estimate VA changes
with the precision used in these studies,
and a sample size of 807 patients
(assuming a 10% dropout) was used.
Statistical analyses were of an explora-
tory and descriptive nature. Analyses
were performed using data from all
patients who received ≥1 anti-VEGF
treatment and had baseline and ≥1
postbaseline assessment of VA for the
study eye and from patients who also
had a VA assessment at month 12
(360  60 days after baseline; ﬁrst-year
completers).
For the primary outcome, the mean
change in VA from baseline (initial visit
prior to ﬁrst ranibizumab therapy injec-
tion) up to month 12 (360  60 days
after baseline) and 95% CI were calcu-
lated; if the patient had two visits during
360  60 days, then the visit closest to
360 days was used. All other follow-up
visits were scheduled within a 30-day
window [e.g. visit 1 (30  15 days) and
visit 12 (360  15 days)]. Visits were
deﬁned as injection or monitoring (non-
injection) visits and could relate to
either study or fellow eye. If injection
and monitoring visits occurred within a
7-day period, then they were counted as
one injection visit. An additional post
hoc analysis was also undertaken to
recount visits on separate dates as sep-
arate visits. To account formissing data,
a last observation carried forward
(LOCF) approach was used for each
window from study start. VA outcomes
were stratiﬁed by country and sub-
groups [sex, age (65, ≥65 years) and
baseline VAS (<60, 61–73, >73 letters)].
Post hoc analyses were undertaken to
explore the association between VA
outcomes, baseline VA and injection
frequency. The statistical evaluation
was performed using the software
package SAS release 9.2 SP4 (SAS
Institute Inc., Cary, NC, USA).
Results
Participants
Overall, 1674 patients were screened
and 983 (58.7%) were enrolled. Of the
691 patients who were not enrolled, 672
were due to screen failures and 19 were
due to study closure (Fig. S1). Out-
comes were analysed from 804 patients
(all patients) and from 568 patients
(ﬁrst-year completers). The main rea-
sons for exclusion were no baseline
(n = 85) or postbaseline (n = 49) visual
acuity assessments (all patients) and no
visual acuity assessment within the
month 12 window (360  60 days)
(n = 236) (ﬁrst-year completers). Over-
all, 98% of patients had some prospec-
tive data, 45% of patients had full
prospective data (all patients), 99% of
patients had some prospective data,
and 45% of patients had full prospec-
tive data (ﬁrst-year completers). The
mean age at baseline was 64.1 years,
and most patients were male (58.3%),
white (65.7%) and had DME in both
eyes (66.4%) (ﬁrst-year completers)
(Table 1). All patients received at least
one ranibizumab injection in the study
eye. A total of 31 patients (all patients)
and 25 patients (ﬁrst-year completers)
also received ≥1 injection of another
anti-VEGF agent.
Functional and anatomical outcomes
The outcomes for both populations
were similar. The mean (SD) baseline
VAS was 59.4 (15.9) letters, and the
proportions of patients with baseline
VAS <69 letters or ≥69 letters were
65% and 35%, respectively (study eye;
ﬁrst-year completers). There was a
gradual improvement to 4.2 letters by
day 90, which was maintained through-
out the study; the ﬁnal mean change in
visual acuity at month 12 was 4.4 letters
(95% CI: 3.3–5.4) (study eye; ﬁrst-year
completers; LOCF) (Fig. 1A and
Table 2) and 4.3 letters (95% CI: 3.2–
5.3) (study eye; observational cohort).
Overall, 29.4% of patients achieved
best-corrected visual acuity gains of
≥10 letters, 17.1% achieved best-cor-
rected visual acuity gains of ≥15 letters,
and 6.7% lost ≥15 letters at month 12
(study eye; ﬁrst-year completers)
(Fig. 1B). The proportion of patients
achieving ≥69 letters at month 12 was
47.4% (study eye; ﬁrst-year com-
pleters). For OCT recordings, most
measurements [91.8% (all patients)
and 90.9% (ﬁrst-year completers)] were
with spectral domain machines at the
last visit. There was a mean reduction
in CRT of 115.2 lm (study eye; ﬁrst-
year completers).
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Resource utilization
Resource use was similar in both pop-
ulations (Table 3). The mean number
of injections (study eye) was 4.9 over
the 12-month period (ﬁrst-year com-
pleters). The mean number of all visits
(for monitoring or injections relating to
either eye) was 10.0 (ﬁrst-year com-
pleters)over the12-monthperiodaccord-
ing to the predeﬁned study set-up. Only
58% (n = 5.8/10.0) were injection visits.
The predeﬁned method allowed multiple
visits made within a window of 7 days to
be documented as a single visit. A post
hoc analysis was undertaken to count
visits made on diﬀerent days as separate
visits to more closely reﬂect the patient
andclinic burden.On this basis, themean
(SD) number of all visits increased only
slightly to 11.3 (4.3) (ﬁrst-year com-
pleters). It must also be noted that
64.9% (all patients)/66.4% (ﬁrst-year
completers) of patients had both eyes
aﬀected by DME; a breakdown of visits
shows that themean (SD) injections/year
in the fellow eye was 3.8 (2.2)/year (all
patients). The percentage of patients
receiving concomitant laser in the study
eye was 27.4% (all patients) and 28.2%
(ﬁrst-year completers), and the percent-
age receiving ocular surgery in the study
eye was 9.5% (all patients) and 10.6%
(ﬁrst-year completers).
Outcomes in subgroups
Visual acuity (VA) outcomes for the
study eye stratiﬁed by country and
subgroups are shown in Table 2. In
general, the majority of countries were
clustered around a mean four-letter
gain, with the exception of Portugal
and Russia, where the letter gains were
0 letters and 8.4 letters, respectively.
Outcomes based on sex and age sub-
groups were comparable and similar to
the overall mean. There was a gain of
8.8 letters in patients with the lowest
baseline VAS (≤60 letters) and a loss of
1.1 letters in patients with the highest
baseline VAS (>73 letters). However,
there was no clear association between
injection numbers and VA outcomes
(Table 2); the mean change in VA at
month 12 was 4.6 letters (<4 injections)
and 4.0 letters (>7 injections). After
adjusting for baseline VA, there was still
no apparent association between injec-
tion numbers and VA outcomes
(Table 4).
Reasons for ending the study
The majority of patients [84.1% (all
patients) and 95.2% (ﬁrst-year com-
pleters)] completed the study; the main
reasons for ending the study early
included loss to follow-up (2.8%),
change of physician (0.5%) and eﬀec-
tiveness achieved (0.4%) (ﬁrst-year
completers) (Fig. S1).
Discussion
POLARIS provides an important over-
view of the 12-month outcomes for
patients with DME treated with rani-
bizumab under real-world settings. The
study showed that the mean change in
visual acuity (VA) was a gain of 4.4
letters at 12 months. This was observed
in the majority of countries, with the
exception of Portugal and Russia;
however, these diﬀerences may be
partly due to the small sample size in
Portugal (ﬁve patients) and the lower
mean baseline VA in Russia (44 let-
ters). Diabetic macular oedema was
also associated with a high treatment
burden for patients and physicians.
Table 1. Patients’ socio-demographic and clinical characteristics at baseline.
Mean (SD) unless stated
All patients
(n = 804)
First-year
completers (n = 568)
Male, n (%) 473 (58.8) 331 (58.3)
Age at baseline, years 64.1 (10.7) 64.1 (10.6)
BMI at baseline, kg/m2 30.04 (5.45) 30.13 (5.71)
Race, n (%)
White 501 (62.3) 373 (65.7)
Asian 23 (2.9) 17 (3.0)
Black 5 (0.6) 5 (0.9)
Other 2 (0.2) 2 (0.4)
Missing or not reported* 273 (34.0) 171 (30.1)
Haemoglobin A1C (%) [n = 216/166] 7.33 (1.18) 7.26 (1.09)
Type of diabetes mellitus, n (%)
Type I 79 (9.8) 54 (9.5)
Type II 724 (90.0) 513 (90.3)
Missing 1 (0.1) 1 (0.2)
Eye aﬀected by DME, n (%)
Right 143 (17.8) 94 (16.5)
Left 139 (17.3) 97 (17.1)
Both 522 (64.9) 377 (66.4)
Study eye
Left 399 (49.6) 289 (50.9)
Right 405 (50.4) 279 (49.1)
Baseline visual acuity score, letters [n = 795/562] 59.7 (15.8) 59.4 (15.9)
Baseline visual acuity score categories, n (%)
<69 letters 526 (65.4) 369 (65.0)
≥69 letters 278 (34.6) 199 (35.0)
Baseline visual acuity score categories, n (%)
≤60 letters 384 (47.8) 272 (47.9)
61–73 letters 261 (32.5) 182 (32.0)
>73 letters 159 (19.8) 114 (20.1)
CRT, lm [n = 664/484] 403.5 (128.9) 410.6 (128.8)
Prior laser treatment (study eye), n (%) 468 (58.2) 341 (60.0)
Focal/grid 277 (34.5) 211 (37.1)
Panretinal 268 (33.3) 194 (34.2)
Laser 35 (4.4) 27 (4.8)
Employment status, n (%)
Employed 133 (16.5) 100 (17.6)
Seeking work 7 (0.9) 5 (0.9)
Retired 327 (40.7) 237 (41.7)
Student 2 (0.2) 1 (0.2)
Keeping house 19 (2.4) 12 (2.1)
Self-employed 11 (1.4) 10 (1.8)
Other 12 (1.5) 6 (1.1)
Not reported/missing 293 (36.4) 197 (34.7)
BMI = body mass index, CRT = central retinal thickness, DME = diabetic macular oedema,
SD = standard deviation.
* Not reported for France and Germany.
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Although patients attended approxi-
mately 10 visits over the year, only
58% of these were treatment visits.
These ﬁndings were similar to those
of other observational studies (Bryn-
skov et al. 2013; Mitchell 2016). An
interim analysis of the LUMINOUS
study showed that the mean change in
VA at 12 months was 4.4 letters in
treatment-na€ıve DME patients and the
mean number of ranibizumab injec-
tions was 3.7 (i.e. a gain of one letter
per injection over 12 months) (Mitchell
2016). However, they do not mirror
those achieved in the active phases of
randomized studies. The mean change
in VA at 12 months was approximately
six letters with ranibizumab as-needed
or treat-and-extend (RESTORE,
RETAIN) and approximately 12 letters
with monthly dosing (RISE/RIDE)
(Mitchell et al. 2011; Nguyen et al.
2012; Prunte et al. 2016). When a sub-
group of patients in the RISE/RIDE
studies were switched to as-needed
ranibizumab treatment from months
36 to 54 (Boyer et al. 2015), the mean
number of injections was 4.5, which was
suﬃcient to maintain VA gains (around
12 letters). Based on these outcomes and
those observed in Protocol I and Pro-
tocol T, which both had intensive
monthly initiation phases, these authors
advocate intensive therapy to maximize
letter gains followed by a reduction in
treatment burden. The regimen used in
POLARIS may be insuﬃcient to max-
imize initial letter gains in patients who
were treatment-na€ıve; this may be a
limitation with as-needed dosing in
routine practice.
Other potential reasons for marked
diﬀerences in VA outcomes achieved in
real-world studies compared with those
achieved in clinical studies may relate
to the fact that measurements in ran-
domized studies are usually best-cor-
rected visual acuity, whereas
observational studies rely on whatever
method the clinic uses. Before analysis,
VA values were converted to a stan-
dard scale using a published standard-
ization chart. Although this is the
normal approach used in observational
studies, it may introduce inconsisten-
cies among clinics and bias in the
conversion chart used. Other issues
include any diﬀerences/similarities in
baseline characteristics (including deﬁ-
nition of worse- or better-seeing eye),
data collection (notably prospective
versus retrospective collection), retreat-
ment criteria and ophthalmologist
adherence to these criteria. For exam-
ple, the mean baseline VAS in
POLARIS was 59.4 letters (ﬁrst-year
completers), which was lower than that
observed in RESTORE (63.5 letters)
(Mitchell et al. 2011). The outcomes in
RESTORE could be limited by a ceil-
ing eﬀect, but based on this, we would
have expected the VA change outcomes
to be greater in POLARIS.
Although all patients started treat-
ment with ranibizumab, some also
received another anti-VEGF agent
(4%) during the observational period
and were included in preplanned anal-
yses. This is consistent with practice in
a real-world setting, and the protocol
in the pivotal Protocol T study also
permitted laser or other DME treat-
ment based on speciﬁc criteria. In the
ranibizumab group of Protocol T, 46%
received laser (from week 24 to year 1)
and <1% received other treatment.
This is somewhat of an ethical imper-
ative, and if many patients need addi-
tional therapy, then a data set could be
diminished by excluding such patients.
However, it does mean that some
patients receiving additional treatment
are included in analyses resulting in
some data mixing. To remove these
patients in POLARIS would be a
violation of the noninterventional pro-
tocol, and given the small numbers, it is
unlikely that the outcome would be
impacted. We acknowledge that it is a
limitation with respect to the outcomes.
Furthermore, IVT-AFL was not
approved at study start, and it was
not possible to derive information on
how many patients would use it. In
Protocol T, IVT-AFL was associated
with a mean gain of 13.3 letters with
9.2 injections, and ranibizumab was
associated with a mean gain of 11.2
letters with 9.4 injections in year 1; this
study followed a protocol in which
injections were initially given monthly
depending on criteria (Wells et al.
2015). The impact of adjuvant laser
was diﬃcult to monitor due to small
patient numbers. Macular laser was
applied to ~ 30% of eyes receiving
ranibizumab 0.5 mg in RISE/RIDE
over 3 years (Brown et al. 2013). In
Table 2. Visual acuity outcomes (LOCF) for all patients stratiﬁed by country, subgroups and
injections.
n
Mean baseline
visual acuity
score (letters)
Mean change
in visual acuity
at month 12
(letters) 95% CI
First-year completers 562 59.4 4.4 3.3–5.4
Country*
France 56 60.7 4.5 0.9–8.1
Germany 95 61.4 3.9 1.2–6.6
Greece 32 61.6 3.4 0.3 to 7.1
Portugal 5 57.6 0.0 10.5 to 10.5
Russia 39 44.1 8.4 3.5–13.2
Slovakia 137 62.0 3.1 1.5–4.6
Spain 73 56.9 4.8 2.2–7.5
UK 125 60.3 5.1 2.5–7.7
Sex*
Male 327 62.0 4.5 3.1–5.8
Female 235 55.9 4.3 2.6–6.0
Age*
<65 years 268 59.6 4.5 3.0–6.1
≥65 years 294 59.3 4.2 2.8–5.6
Baseline visual acuity score categories*
≤60 letters 266 46.3 8.8 7.2–10.4
61–73 letters 182 67.4 1.5 –0.0 to 2.9
>73 letters 114 77.3 –1.1 –3.1 to 0.8
Injection categories (4-level)*
<4 184 58.6 4.6 2.9–6.3
4–5 156 60.4 4.3 2.2–6.5
6–7 116 59.6 4.4 2.1–6.7
>7 106 59.2 4.0 1.6–6.4
CI = conﬁdence interval, SD = standard deviation.
* First-year completers.
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Protocol T, deferred laser was used in
41% of IVT-AFL patients, 64% of
bevacizumab patients and 52% of
ranibizumab patients over 2 years; a
subanalysis revealed that laser treat-
ment could have positively impacted
the central subﬁeld thickness reductions
in patients with worse vision in the
bevacizumab group (Jampol et al. 2016;
Wells et al. 2016). In RESTORE, VA
gains at 12 months were similar in
patients receiving ranibizumab with or
without concomitant laser (Mitchell
et al. 2011).
Itmust be noted that therewas a large
diﬀerence in patient numbers between
the ‘all patients’ and ‘ﬁrst-year com-
pleters’; this does not indicate selection
bias, but highlights the lack of strict
inclusion criteria in an observational
design study and reﬂects clinical practice
with respect to treatment use at
12 months. It was also diﬃcult to deter-
mine associations between number of
injections and VA outcomes in sub-
groups due to small patient numbers,
and the study was not designed to assess
these in detail. As opposed to random-
ized studies, which follow strict proto-
cols, dosing in real-world studiesmay be
reactive (i.e. in response to outcomes),
and achievement of short-term gains
may result in reduction of future injec-
tions despite the possibility of further
improvement; this was evidenced in
POLARIS (Table 4), which indicates
that outcomes seem to drive injections
Fig. 1. Visual acuity outcomes for all patients and ﬁrst-year completers including (A) mean
change in visual acuity (LOCF) from baseline to month 12 and (B) loss or gain of letters (LOCF)
at month 12. LOCF = last observation carried forward. *Deﬁnition of ﬁrst-year visit: the visit
closest to 360 days from baseline within 360  60 day window. Data not available for all patients
at all time points.
Table 3. Resource use for all patients and by country* (LOCF).
Mean (SD in
brackets) unless
stated All patients
First-year
completers France Germany Greece Portugal Russia Slovakia Spain UK
n 804 568 60 95 32 5 40 137 74 125
Injections† 4.5 (2.3) 4.9 (2.4) 4.5 (2.0) 5.1 (2.1) 4.2 (1.9) 5.6 (0.9) 2.0 (1.2) 4.6 (1.8) 4.1 (2.3) 6.7 (2.3)
All visits 9.1 (4.0) 10.0 (3.9) 9.3 (2.2) 12.5 (6.7) 9.3 (3.1) 7.6 (0.5) 5.8 (1.4) 10.9 (2.9) 8.7 (2.1) 9.8 (2.4)
Injection visits 5.4 (2.9) 5.8 (2.9) 5.0 (2.2) 6.3 (3.4) 5.3 (2.5) 5.8 (0.8) 2.3 (1.4) 6.2 (2.8) 4.7 (2.5) 7.4 (2.4)
Monitoring visits 3.7 (3.2) 4.1 (3.4) 4.3 (2.1) 6.2 (6.0) 3.9 (2.3) 1.8 (0.8) 3.5 (1.2) 4.6 (2.1) 4.0 (2.8) 2.4 (2.0)
Visual acuity
tests
9.1 (4.0) 10.0 (3.9) 9.3 (2.2) 12.5 (6.7) 9.3 (3.1) 7.6 (0.5) 5.8 (1.4) 10.9 (2.9) 8.7 (2.1) 9.8 (2.4)
OCT 5.9 (3.4) 6.8 (3.3) 6.4 (2.2) 4.2 (3.5) 7.2 (2.4) 5.0 (1.4) 4.7 (1.6) 9.4 (3.2) 6.9 (2.2) 6.7 (2.8)
Ophthalmoscopy 7.2 (5.9) 8.1 (6.3) 3.9 (3.8) 9.3 (4.3) 7.2 (5.8) 3.2 (1.1) 8.2 (2.6) 14.8 (6.8) 5.8 (2.3) 3.5 (3.7)
FA 0.7 (1.0) 0.7 (1.0) 0.4 (0.6) 1.7 (1.3) 0.7 (0.5) 0.4 (0.5) 0.1 (0.3) 0.8 (0.9) 0.6 (0.7) 0.2 (0.4)
Concomitant
laser†, n (%)
220 (27.4) 160 (28.2) 11 (18.3) 26 (27.4) 10 (31.3) 1 (20.0) 16 (40.0) 61 (44.5) 18 (24.3) 17 (13.6)
FA = ﬂuorescein angiography, LOCF = last observation carried forward, OCT = optical coherence tomography, SD = standard deviation.
* First-year completers.
† Study eye.
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as much as injections drive outcomes
when using as-needed regimens in
DME. This may partly explain the lack
of association between injection fre-
quency and VA outcomes. It could also
be driven by disease characteristics at
baseline.
We did not determine how patients’
access to treatment and arrangement
for reimbursement of provider costs in
each healthcare system aﬀected resource
use during the study and, therefore,
outcomes. It is notable that like AURA
(Holz et al. 2015), injection rates and
VA gains were generally greater in the
UK than in other countries (Table 2);
this is similar to ﬁndings observed in
another real-world study in the UK
setting in which 164 patients with DME
received an average of 7.2 ranibizumab
injections and an increase of 6.6 letters
over 12 months (Patrao et al. 2016).
Patients of the UK National Health
Service are not required to seekapproval
for physician-prescribed treatment with
ranibizumab or IVT-AFL or to make
copayments for treatments or visits.
Restrictions in healthcare systems may,
in part, account for some of the variation
in outcomes observed between countries.
Access to ophthalmology facilities may
also be an issue in some countries (Mar-
ques et al. 2015).This alsohighlights that
any diﬀerences in the number of patients
enrolled between diﬀerent clinics and
countries could introduce bias in the
current study.
In conclusion, POLARIS showed that
real-world outcomes with ranibizumab
were suboptimal in comparison with
clinical studies, in spite of extensive
monitoring. It is potentially linked to
an insuﬃcient number of intravitreal
injections in real-life studies, but it must
be noted that a real-world setting is very
diﬀerent from a randomized study. Since
data collection for the current analysis,
the labelled ranibizumab regimen
changed from as-needed with monthly
monitoring to a more ﬂexible approach
guided by the physician; the impact of
this change on treatment practice needs
to be fully determined.
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